SI1948620T1 - Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja - Google Patents

Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja

Info

Publication number
SI1948620T1
SI1948620T1 SI200631572T SI200631572T SI1948620T1 SI 1948620 T1 SI1948620 T1 SI 1948620T1 SI 200631572 T SI200631572 T SI 200631572T SI 200631572 T SI200631572 T SI 200631572T SI 1948620 T1 SI1948620 T1 SI 1948620T1
Authority
SI
Slovenia
Prior art keywords
prostaglandin
receptor antagonist
dihydrogen phosphate
phosphate salt
salt
Prior art date
Application number
SI200631572T
Other languages
English (en)
Inventor
Beverly Langevin
Edward Orton
Daniel Sherer
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SI1948620T1 publication Critical patent/SI1948620T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200631572T 2005-10-13 2006-10-12 Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja SI1948620T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13
EP06825836A EP1948620B1 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
PCT/US2006/039901 WO2007047378A2 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (1)

Publication Number Publication Date
SI1948620T1 true SI1948620T1 (sl) 2013-05-31

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631572T SI1948620T1 (sl) 2005-10-13 2006-10-12 Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja

Country Status (36)

Country Link
US (1) US7642249B2 (sl)
EP (1) EP1948620B1 (sl)
JP (1) JP2009511591A (sl)
KR (1) KR101365480B1 (sl)
CN (1) CN101287714B (sl)
AR (1) AR058085A1 (sl)
AU (1) AU2006304187B2 (sl)
BR (1) BRPI0617311A2 (sl)
CA (1) CA2625563C (sl)
CR (1) CR9870A (sl)
DK (1) DK1948620T3 (sl)
DO (2) DOP2006000220A (sl)
EC (1) ECSP088362A (sl)
ES (1) ES2409833T3 (sl)
GT (1) GT200600457A (sl)
HK (1) HK1125133A1 (sl)
HN (1) HN2008000603A (sl)
HR (1) HRP20130341T1 (sl)
IL (1) IL190673A (sl)
MA (1) MA30005B1 (sl)
MY (1) MY145648A (sl)
NI (1) NI200800116A (sl)
NO (1) NO20082072L (sl)
NZ (1) NZ567433A (sl)
PE (1) PE20070791A1 (sl)
PL (1) PL1948620T3 (sl)
PT (1) PT1948620E (sl)
RS (1) RS52799B (sl)
RU (1) RU2419614C2 (sl)
SI (1) SI1948620T1 (sl)
TN (1) TNSN08131A1 (sl)
TW (1) TW200728288A (sl)
UA (1) UA93062C2 (sl)
UY (1) UY29862A1 (sl)
WO (1) WO2007047378A2 (sl)
ZA (1) ZA200802586B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
CN101490001A (zh) * 2006-06-09 2009-07-22 Icos股份有限公司 用作dp-2拮抗剂的取代的苯乙酸
JP2010532366A (ja) * 2007-06-29 2010-10-07 サノフィ−アベンティス ２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
EP2590640A1 (en) 2010-07-08 2013-05-15 Ramot at Tel-Aviv University Ltd Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
US8785467B2 (en) * 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
CU24496B1 (es) 2015-06-04 2021-01-12 Aurigene Discovery Tech Ltd Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk
WO2019055661A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469316A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
RU2006103655A (ru) * 2003-07-09 2007-08-20 Ф.Хоффманн-Ля Рош Аг (Ch) Тиофениламиноимидазолины
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
DK1948620T3 (da) 2013-06-24
NI200800116A (es) 2011-12-15
KR20080057275A (ko) 2008-06-24
IL190673A (en) 2011-12-29
PT1948620E (pt) 2013-05-06
AU2006304187A1 (en) 2007-04-26
EP1948620B1 (en) 2013-03-20
GT200600457A (es) 2007-04-27
EP1948620A2 (en) 2008-07-30
US20080194600A1 (en) 2008-08-14
NO20082072L (no) 2008-05-02
WO2007047378A2 (en) 2007-04-26
JP2009511591A (ja) 2009-03-19
RS52799B (en) 2013-10-31
CR9870A (es) 2008-06-18
NZ567433A (en) 2010-06-25
AU2006304187B2 (en) 2011-04-28
ZA200802586B (en) 2009-09-30
ES2409833T3 (es) 2013-06-28
CN101287714A (zh) 2008-10-15
UY29862A1 (es) 2007-05-31
UA93062C2 (ru) 2011-01-10
KR101365480B1 (ko) 2014-02-21
DOP2006000220A (es) 2007-05-15
HN2008000603A (es) 2010-11-03
PL1948620T3 (pl) 2013-08-30
MY145648A (en) 2012-03-15
CA2625563A1 (en) 2007-04-26
US7642249B2 (en) 2010-01-05
DOP2006000223A (es) 2007-05-15
AR058085A1 (es) 2008-01-23
CA2625563C (en) 2011-04-19
HRP20130341T1 (en) 2013-05-31
CN101287714B (zh) 2011-04-06
TW200728288A (en) 2007-08-01
PE20070791A1 (es) 2007-08-16
BRPI0617311A2 (pt) 2011-07-19
RU2419614C2 (ru) 2011-05-27
TNSN08131A1 (en) 2009-07-14
IL190673A0 (en) 2008-11-03
WO2007047378A3 (en) 2007-08-02
HK1125133A1 (en) 2009-07-31
RU2008118491A (ru) 2009-11-20
ES2409833T8 (es) 2013-09-26
MA30005B1 (fr) 2008-12-01
ECSP088362A (es) 2008-05-30

Similar Documents

Publication Publication Date Title
HRP20130341T1 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
IL268462A (en) Dosage form of risedronate
HUS000508I2 (hu) Oszilodrosztát vagy gyógyszerészetileg elfogadható sója, beleértve az oszilodrosztát-dihidrogén-foszfátot
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL213070A (en) A method for determining the efficacy of PD-1 antagonist
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
HK1151285A1 (zh) 凝血酶受體拮抗劑的硫酸氫鹽的結晶多晶型物
HK1131975A1 (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
PL2662380T3 (pl) Medyczne zastosowanie polimorfu A Ibandronianu
PL2146944T3 (pl) Sposób otrzymywania folianów znakowanych fluorem-18
IL187362A0 (en) Derivatives of a 1-phenyltriazole as antiparasitic agents
IL195903A0 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
PL380663A1 (pl) Amorficzne postaci rizedronianu monosodowego
GB2428679B (en) Methods of forming a barrier
ZA200809171B (en) Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group
ZA200806508B (en) Salt of CD80 Antagonist
EP2061492A4 (en) PROCESS FOR AFFECTING PAIN BY MODIFYING NMDA RECEPTORS BY INHIBITION OF SRC
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
IL196402A0 (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
HK1117141A1 (en) Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
PL2225187T3 (pl) Otrzymywanie kompozycji opartej na fosforanie potasu
GB0800684D0 (en) Method for determining the status of a body